Brainstorm Cell Therapeutics Inc (NAS:BCLI)
$ 2.35 0.12 (5.38%) Market Cap: 12.72 Mil Enterprise Value: 13.39 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 29/100

Q1 2020 Brainstorm Cell Therapeutics Inc Earnings Call Transcript

May 07, 2020 / 12:30PM GMT
Release Date Price: $88.65 (-12.31%)
Operator

Good day and welcome to the Brainstorm Cell Therapeutics first-quarter 2020 conference call. At this time, all participants are in a listen-only mode. As a reminder, this call is recorded.

And I would now like to introduce your host for today's conference, Mr. Sean Leous from ICR Westwicke. Mr. Leous, you may begin.

Sean Leous
ICR Westwicke - IR

Thank you for joining the Brainstorm Cell Therapeutics call.

Before we begin, the opening remarks. We would like to remind listeners that this conference call contains numerous statements, descriptions, forecasts, and projections regarding Brainstorm Cell Therapeutics, NASDAQ: BCLI, and its potential future business operations and performance, statements regarding the market potential for the treatment of neurodegenerative disorders such as ALS and MS, the sufficiency of our existing capital resources for continuing operations in 2020 and beyond, the safety and clinical effectiveness of our NurOwn technology platform, our clinical trials of NurOwn and related clinical development programs and our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot